0.02
-13.64%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Argent Biopharma
Its shares trade on ASX under the ticker RGT.AX. It has been listed since 21 December 2006. In the fiscal year to 30 June 2026, it reported revenue of A$161,187 and a net loss of A$7.7m. At that date it held total assets of A$1.3m and shareholders' equity of −A$9.4m.
MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. The firm is primarily focused on the development and supply of standardized phytomedicines to patients globally. The company has three clinical projects, as well as a pipeline of therapies: CimetrA, a Phase III symptomatic treatment for early COVID-19; CannEpil, a Phase IIb cannabis-based therapy for drug-resistant Epilepsy; CogniCann, in a Phase II trial for symptomatic relief of Dementia, and Irnican, a preclinical medicine to be used for treatment for Glioblastoma. The firm is focused on the ArtemiC range of products, and its cannabinoid products are primarily distributed within Australia, the United Kingdom and South America. The company has a product offering targeting two medical conditions, which include epilepsy and dementia. The firm's wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 21 Dec 2006
- Website
- mgcpharma.com.au ↗
Leadership
Pay as last reported
- Mr. Roby ZomerChief Executive Officer, Managing Director, Executive Director, since 2016A$629,362
- Ms. Yifat SteuerDeputy Chief Executive Officer, Chief Operating Officer
- Mr. Igor BluvsteinChief Financial Officer
- Mr. Robert ClementsChief Commercial Officer
- Mr. Rowan HarlandCompany Secretary
- Mr. Gary HermonNon-Executive Director
- Mr. Layton MillsNon-Executive Director
- Mr. Daniel RobinsonNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- MGC Pharmaceuticals Ltd develops standardized phytomedicines for global patients with three clinical projects.
- CimetrA is a Phase III treatment for early COVID-19 symptoms targeting global markets.
- CannEpil is a Phase IIb cannabis-based therapy for drug-resistant epilepsy in clinical trials.
Weaknesses
- MGC Pharma (UK) Limited focuses on the United Kingdom market with limited global expansion.
- CogniCann targets dementia with a Phase II trial in a competitive medical field.
- Irnican is a preclinical medicine for Glioblastoma with no current market presence.
Opportunities
- The ArtemiC product range targets epilepsy and dementia medical conditions globally.
- MGC Research (Aus) Pty Ltd supports clinical trials in Australia for cannabinoid therapies.
- Medicinal Cannabis Clinics Pty Ltd provides distribution channels in South America.
Threats
- The company's cannabinoid products are distributed primarily within Australia, the United Kingdom, and South America.
- CimetrA faces competition in the Phase III treatment market for early COVID-19.
- CannEpil must navigate regulatory challenges for cannabis-based therapies in the United States.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.